↓ Skip to main content

Exosome-Based Cancer Therapy: Implication for Targeting Cancer Stem Cells

Overview of attention for article published in Frontiers in Pharmacology, January 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

twitter
52 X users
patent
1 patent
facebook
1 Facebook page

Citations

dimensions_citation
187 Dimensions

Readers on

mendeley
271 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Exosome-Based Cancer Therapy: Implication for Targeting Cancer Stem Cells
Published in
Frontiers in Pharmacology, January 2017
DOI 10.3389/fphar.2016.00533
Pubmed ID
Authors

Jinheng Wang, Yongjiang Zheng, Meng Zhao

Abstract

Drug resistance, difficulty in specific targeting and self-renewal properties of cancer stem cells (CSCs) all contribute to cancer treatment failure and relapse. CSCs have been suggested as both the seeds of the primary cancer, and the roots of chemo- and radio-therapy resistance. The ability to precisely deliver drugs to target CSCs is an urgent need for cancer therapy, with nanotechnology-based drug delivery system being one of the most promising tools to achieve this in the clinic. Exosomes are cell-derived natural nanometric vesicles that are widely distributed in body fluids and involved in multiple disease processes, including tumorigenesis. Exosome-based nanometric vehicles have a number of advantages: they are non-toxic, non-immunogenic, and can be engineered to have robust delivery capacity and targeting specificity. This enables exosomes as a powerful nanocarrier to deliver anti-cancer drugs and genes for CSC targeting therapy. Here, we will introduce the current explorations of exosome-based delivery system in cancer therapy, with particular focus on several exosomal engineering approaches that have improved their efficiency and specificity for CSC targeting.

X Demographics

X Demographics

The data shown below were collected from the profiles of 52 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 271 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
United States 1 <1%
Denmark 1 <1%
Unknown 268 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 49 18%
Student > Master 37 14%
Student > Bachelor 36 13%
Researcher 26 10%
Student > Doctoral Student 12 4%
Other 38 14%
Unknown 73 27%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 68 25%
Agricultural and Biological Sciences 24 9%
Medicine and Dentistry 19 7%
Engineering 16 6%
Pharmacology, Toxicology and Pharmaceutical Science 12 4%
Other 44 16%
Unknown 88 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 37. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 May 2022.
All research outputs
#1,134,250
of 26,166,431 outputs
Outputs from Frontiers in Pharmacology
#429
of 20,138 outputs
Outputs of similar age
#22,978
of 428,560 outputs
Outputs of similar age from Frontiers in Pharmacology
#6
of 171 outputs
Altmetric has tracked 26,166,431 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 20,138 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 428,560 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 171 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.